[go: up one dir, main page]

MX2019006940A - Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar. - Google Patents

Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar.

Info

Publication number
MX2019006940A
MX2019006940A MX2019006940A MX2019006940A MX2019006940A MX 2019006940 A MX2019006940 A MX 2019006940A MX 2019006940 A MX2019006940 A MX 2019006940A MX 2019006940 A MX2019006940 A MX 2019006940A MX 2019006940 A MX2019006940 A MX 2019006940A
Authority
MX
Mexico
Prior art keywords
bipolar disorder
relief
prevention
treatment
carbamate compounds
Prior art date
Application number
MX2019006940A
Other languages
English (en)
Inventor
Jin Shin Yu
Myoung Han Sei
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of MX2019006940A publication Critical patent/MX2019006940A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona al uso para el propósito de prevenir, aliviar o tratar el trastorno bipolar al administrar una composición farmacéutica que comprende un compuesto de carbamato de la siguiente fórmula química 1.
MX2019006940A 2016-12-14 2017-12-14 Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar. MX2019006940A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160170224 2016-12-14
PCT/KR2017/014740 WO2018111008A1 (ko) 2016-12-14 2017-12-14 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도

Publications (1)

Publication Number Publication Date
MX2019006940A true MX2019006940A (es) 2019-09-06

Family

ID=62559442

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006940A MX2019006940A (es) 2016-12-14 2017-12-14 Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar.

Country Status (14)

Country Link
US (1) US11571410B2 (es)
EP (1) EP3556366B1 (es)
JP (1) JP7208139B2 (es)
KR (1) KR102635938B1 (es)
CN (1) CN110290788A (es)
AU (1) AU2017374458B2 (es)
BR (1) BR112019011930A2 (es)
CA (1) CA3046297A1 (es)
CL (1) CL2019001618A1 (es)
IL (1) IL267195B2 (es)
MX (1) MX2019006940A (es)
MY (1) MY199104A (es)
WO (1) WO2018111008A1 (es)
ZA (1) ZA201903747B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12070448B2 (en) * 2018-09-21 2024-08-27 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for prevention, alleviation or treatment of status epilepticus
US20220117941A1 (en) * 2018-09-21 2022-04-21 Sk Biopharmaceuticals Co., Ltd. Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
US20230000763A1 (en) * 2019-11-22 2023-01-05 Sk Biopharmaceuticals Co., Ltd. Oral pharmaceutical composition comprising carbamate compound and preparation method therefor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1154489C (zh) * 1997-08-14 2004-06-23 弗·哈夫曼-拉罗切有限公司 抗神经学疾病的杂环乙烯基醚
JP2004520263A (ja) * 2000-07-21 2004-07-08 テバ　ファーマシューティカル　インダストリーズ　リミティド 双極性障害における躁病を治療するためのバルプロ酸および２−バルプロエン酸アミド誘導体の使用
BR0207832A (pt) 2001-02-27 2004-06-22 Ortho Mcneil Pharm Inc Compostos de carbamato para uso na prevenção ou tratamento de distúrbio bipolar
CN1250215C (zh) * 2001-02-27 2006-04-12 奥索-麦克尼尔药品公司 用于预防或治疗双相性精神障碍的氨基甲酸酯化合物
EA200701065A1 (ru) 2004-11-16 2007-12-28 Элан Фарма Интернэшнл Лтд. Инъецируемые составы, содержащие нанодисперсный оланзапин
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
MX2009004798A (es) * 2006-10-31 2009-08-12 Janssen Pharmaceutica Nv Tratamiento de los trastornos generalizados del desarrollo.
CA2765566C (en) 2009-06-22 2016-04-12 Sk Biopharmaceuticals Co., Ltd. Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US9610274B2 (en) * 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
ES2791186T3 (es) 2014-08-15 2020-11-03 Janssen Pharmaceuticals Inc Triazoles como inhibidores de receptores NR2B

Also Published As

Publication number Publication date
CA3046297A1 (en) 2018-06-21
KR102635938B1 (ko) 2024-02-13
AU2017374458A1 (en) 2019-07-04
IL267195A (es) 2019-07-31
CN110290788A (zh) 2019-09-27
BR112019011930A2 (pt) 2019-10-29
MY199104A (en) 2023-10-13
US20190314337A1 (en) 2019-10-17
EP3556366A1 (en) 2019-10-23
ZA201903747B (en) 2021-01-27
JP7208139B2 (ja) 2023-01-18
CL2019001618A1 (es) 2019-08-23
JP2020502106A (ja) 2020-01-23
WO2018111008A1 (ko) 2018-06-21
EP3556366B1 (en) 2025-10-22
RU2019121913A (ru) 2021-01-15
EP3556366A4 (en) 2020-06-17
IL267195B2 (en) 2024-05-01
KR20190087572A (ko) 2019-07-24
US11571410B2 (en) 2023-02-07
RU2019121913A3 (es) 2021-04-21
IL267195B1 (en) 2024-01-01
AU2017374458B2 (en) 2023-03-02

Similar Documents

Publication Publication Date Title
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
DOP2021000017A (es) Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos
CO2020007162A2 (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
GT201500092A (es) Moduladores de quinolinillo unidos a fenilo de ror-gamma-t
UY36340A (es) Derivados de indoles mono- o disustituidos como inhibidores de la replicación del virus del dengue
PH12021500034A1 (en) Compounds useful in hiv therapy
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
MX2022000945A (es) Composicion para incrementar la expresion de pgc-1alfa.
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
MX2021001612A (es) Compuestos utiles en terapia del vih.
DOP2020000077A (es) Nuevo derivado de fenilpiridina y composición farmacéutica que lo contiene
MX2020004930A (es) Compuestos de biarilo sustituido novedosos como inhibidores de indolamina 2,3-dioxigenasa (ido).
NZ757526A (en) Naphthoquinones, their derivatives and uses thereof in methods for the treatment of mitochondrial dysfunction
MX2019006940A (es) Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar.
MX2019004842A (es) Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc.
MX392555B (es) Composiciones y métodos para el tratamiento de resistencia a la insulina.
CO2019007836A2 (es) Derivados de pirrolotriazina como inhibidor de cinasas
MX2018014081A (es) Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.
CL2019001623A1 (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el síndrome de temblor.
MX2021004342A (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar neuropatía periférica diabética o neuropatía periférica inducida por quimioterapia.
BR112015028884A2 (pt) tratamento ou prevenção de depressão utilizando mentol e/ou icilina
TR201906539T4 (tr) Mentol, Linalool ve/veya Icilin Kullanarak Beyin Travması ve İnmelerden Kaynaklanan Non-İnflamatuar Nöron Hasarının Tedavisi veya Önlenmesi.